Journal
JOURNAL OF GENE MEDICINE
Volume 10, Issue 2, Pages 217-224Publisher
JOHN WILEY & SONS LTD
DOI: 10.1002/jgm.1140
Keywords
congenital muscular dystrophy; laminin alpha 2 chain; premature termination codon; antibiotic-mediated readthrough; nonsense-mediated mRNA decay
Ask authors/readers for more resources
Background The most common form of congenital muscular dystrophy is caused by a deficiency in the alpha 2 chain of laminin-211, a protein of the extracellular matrix. A wide variety of mutations, including 20 to 30% of nonsense mutations, have been identified in the corresponding gene, LAMA2. A promising approach for the treatment of genetic disorders due to premature termination codons (PTCs) is the use of drugs to force stop codon readthrough. Methods Here, we analyzed the effects of two compounds on a PTC in the LAMA2 gene that targets the mRNA to nonsense-mediated RNA decay, in vitro using a dual reporter assay, as well as ex vivo in patient-derived myotubes. Results We first showed that both gentamicin and negamycin promote significant readthrough of this PTC. We then demonstrated that the mutant mRNAs were strongly stabilized in patient-derived myotubes after administration of negamycin, but not gentamicin. Nevertheless, neither treatment allowed re-expression of the laminin alpha 2-chain protein, pointing to problems that may have arisen at the translational or post-translational levels. Conclusions Taken together, our results emphasize that achievement of a clinical benefit upon treatment with novel readthrough-inducing agents would require several favourable conditions including PTC nucleotide context, intrinsic and induced stability of mRNA and correct synthesis of a full-length active protein. Copyright (C) 2007 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available